Jump Financial’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Jump Financial’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-65,109	Closed	-$5.44M	–	2110
2024 Q4	$5.44M	Buy	65,109 +8,457	+15%	+$695K	0.11%	238
2024 Q3	$4.15M	Sell	56,652 -6,237	-10%	-$469K	0.08%	280
2024 Q2	$4.31M	Buy	+62,889	New	+$4.36M	0.09%	270
2024 Q1	–	Sell	-14,600	Closed	-$1.05M	–	2387
2023 Q4	$1.05M	Sell	14,600 -42,128	-74%	-$2.42M	0.03%	701
2023 Q3	$2.95M	Buy	56,728 +53	+0.1%	+$3.09K	0.11%	240
2023 Q2	$3.59M	Sell	56,675 -43,156	-43%	-$2.69M	0.13%	194
2023 Q1	$5.41M	Buy	99,831 +46,822	+88%	+$2.26M	0.22%	138
2022 Q4	$2.81M	Buy	53,009 +43,009	+430%	+$2.16M	0.15%	183
2022 Q3	$465K	Buy	+10,000	New	+$522K	0.02%	922
2020 Q4	–	Sell	-33,117	Closed	-$850K	–	1220
2020 Q3	$850K	Buy	+33,117	New	+$756K	0.17%	170

Other funds holding ITCI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

HBK Investments Dallas, Texas $10.3B AUM 67.69% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Jump Financial's ITCI Position: Q1 2025 in Review

Jump Financial sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 65,109 shares — an estimated $5.44M sold.

Jump Financial first reported a position in ITCI in Q3 2020 and held it in 10 quarters. The position peaked at $5.44M in Q4 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

Jump Financial reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
Jump Financial sold 65,109 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $5.44M.
Jump Financial first reported a position in Intra-Cellular Therapies Inc. in Q3 2020 and held it in 10 quarters.
Jump Financial's Intra-Cellular Therapies Inc. position peaked at $5.44M in Q4 2024.
395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Jump Financial's 13F filing for Q1 2025, filed 14 May 2025.